# Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

> **NCT02206503** · PHASE2 · COMPLETED · sponsor: **Fondazione EMN Italy Onlus** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02206503
- **Lead sponsor:** Fondazione EMN Italy Onlus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-04
- **Final completion:** 2018-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206503, "Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02206503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*